Crinetics Pharmaceuticals Stock Quote CRNX - Stock Price, News, Charts, Message Board, Trades

Professional-Grade Tools, for Individual Investors.

Premium

Current Price

57.01

Bid

51.95

Ask

64.14

Volume

893

0.00 Day's Range 0.00

29.72 52 Week Range 67.51

Market Cap

5.287B

Previous Close

56.07

Open

Last Trade

59.43

Last Trade Time

08:29:43

Financial Volume

VWAP

Average Volume (3m)

725,124

Shares Outstanding

92,737,627

Dividend Yield

PE Ratio

-24.24

Earnings Per Share (EPS)

-2.31

Revenue

4.01M

Net Profit

-214.53M

Crinetics Pharmaceuticals Inc is a clinical-stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. Crinetics Pharmaceuticals Inc is a clinical-stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors.

Sector

Pharmaceutical Preparations

Industry

Pharmaceutical Preparations

Website

www.crinetics.com

Headquarters

Wilmington, Delaware, USA

Founded

Crinetics Pharmaceuticals Inc is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker CRNX. The last closing price for Crinetics Pharmaceuticals was $56.07. Over the last year, Crinetics Pharmaceuticals shares have traded in a share price range of $ 29.72 to $ 67.51.

Crinetics Pharmaceuticals currently has 92,737,627 shares outstanding. The market capitalization of Crinetics Pharmaceuticals is $5.20 billion. Crinetics Pharmaceuticals has a price to earnings ratio (PE ratio) of -24.24.

Crinetics Pharmaceuticals to Participate in Three Upcoming December Investor Conferences

SAN DIEGO, Nov. 15, 2024 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical stage pharmaceutical company focused on the discovery, development and commercialization...

UPDATE: Crinetics Pharmaceuticals to Showcase Pipeline Advancements with Neuroendocrine Tumor Candidates at The North American Neuroendocrine Tumor Society (NANETS) Annual Meeting

Novel Nonpeptide Drug Conjugate Platform to be Debuted, Featuring Preclinical Profile of Lead Candidate CRN09682 Targeting SST2-Expressing Tumors, which is on Track for IND Submission Early 2025...

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Form 8-K - Current report

Crinetics Pharmaceuticals to Showcase Pipeline Advancements with Neuroendocrine Tumor Candidates at The North American Neuroendocrine Tumor Society (NANETS) Annual Meeting

Novel Nonpeptide Drug Conjugate Platform to be Debuted, Featuring Preclinical Profile of Lead Candidate CRN09682 Targeting SST2-Expressing Tumors, which is on Track for IND Submission Early 2025...

Period	Change	Change %	Open	High	Low	Avg. Daily Vol	VWAP
1	-1.27	-2.17913520933	58.28	67.51	52.845	726636	55.92660319	CS
4	-1.49	-2.54700854701	58.5	67.51	52.845	621813	57.62783337	CS
12	2.44	4.47132123878	54.57	67.51	49.125	725124	54.63927012	CS
26	6.44	12.7348230176	50.57	67.51	41.01	752102	51.53178103	CS
52	26.86	89.087893864	30.15	67.51	29.72	786763	45.81997027	CS
156	29.48	107.083181983	27.53	67.51	15.23	600935	32.80172799	CS
260	37.83	197.236704901	19.18	67.51	10.63	421954	30.60972565	CS

Most Active
% Gainers
% Losers

Symbol	Price	Vol.
SPAISafe Pro Group Inc	$ 5.92 (85.00%)	8.5M
WORXSCWorx Corporation	$ 1.75 (78.57%)	25.72M
CDTConduit Pharmaceuticals Inc	$ 0.1463 (58.50%)	147.33M
AKTSAkoustis Technologies Inc	$ 0.124 (42.37%)	118.52M
ESGROEnstar Group Ltd	$ 28.00 (40.92%)	29
WSBFWaterstone Financial Inc	$ 9.00 (-40.98%)	6
TRSTriMas Corporation	$ 15.62 (-40.79%)	4
BCAXBicara Therapeutics Inc	$ 11.00 (-40.15%)	316
PYXSPyxis Oncology Inc	$ 2.33 (-39.01%)	1.5M
XNCRXencor Inc	$ 15.11 (-36.30%)	35
CDTConduit Pharmaceuticals Inc	$ 0.1472 (59.48%)	147.49M
AKTSAkoustis Technologies Inc	$ 0.124 (42.37%)	118.58M
PETWag Group Company	$ 0.2711 (29.03%)	26.22M
WORXSCWorx Corporation	$ 1.75 (78.57%)	25.72M
NVDANVIDIA Corporation	$ 147.80 (1.31%)	12.99M